Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

C3 Jian raises $60.5mm through Series D round

Executive Summary

C3 Jian Inc. (using a cell signaling technology to develop drugs and diagnostics for oral health and infectious conditions) raised $60.5mm through its Series D round. Renaissance Holding Co. (a dental insurance holding company) led, and was joined by affiliates of dental benefits administrator Delta Dental, and other new and returning investors. Proceeds will fund Phase II trials of C3's antimicrobial peptide C16G2 for Streptococcus mutans (contributes to tooth decay), and to advance another peptide candidate for teeth remineralization and hair/nail growth.
Deal Industry
  • Biotechnology
    • Large Molecule
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Medical Devices
    • Diagnostic Equipment & Supplies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies